Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

KMT2E-Related Neurodevelopmental Disorder

Lynn Pais  1 , Lance Rodan  1 , Anne O'Donnell-Luria  1
Margaret P Adam, Jerry Feldman, Ghayda M Mirzaa, Roberta A Pagon, Stephanie E Wallace, Anne Amemiya
, editors.
In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
.
Affiliations
Free Books & Documents
Review

KMT2E-Related Neurodevelopmental Disorder

Lynn Pais et al.
Free Books & Documents

Excerpt

Clinical characteristics: KMT2E-related neurodevelopmental disorder (KMT2E-NDD) is a condition characterized by global developmental delay, variable intellectual disability (typically in the mild-to-moderate range), and hypotonia. The majority of affected individuals are verbal but experience speech delays with or without articulation problems. All reported individuals who are older than infants have been able to obtain independent ambulation. About one third of affected individuals develop seizures, with no consistent seizure semiology or epilepsy syndrome. However, females may be more likely to develop seizures compared to males. Similarly, about one third of affected individuals have an autism spectrum disorder diagnosis, of which most to date are male. Growth parameters are typically in the normal range for length/height and weight, although about half of affected individuals have macrocephaly or relative macrocephaly. Constipation is the most frequent gastrointestinal issue, although gastroesophageal reflux, vomiting, and/or reduced bowel motility have been reported in almost half of affected individuals. About half of affected individuals experience some type of sleep disturbance, including frequent awakening and difficulties falling asleep.

Diagnosis/testing: The diagnosis of KMT2E-NDD is established in a proband with suggestive findings and a heterozygous pathogenic variant in KMT2E identified by molecular genetic testing.

Management: Treatment of manifestations: Standard treatment for developmental delay / intellectual disability, neuropsychiatric issues, seizures, constipation, gastroesophageal reflux/dysmotility, vomiting, and sleep disturbance.

Surveillance: At each visit, measure growth parameters (including head circumference); assess for new neurologic manifestations and monitor those with seizures as clinically indicated; monitor developmental progress and educational need; assess for behavioral issues, including anxiety, ADHD, aggression, and self-injury; and assess for chronic vomiting, constipation, and signs/symptoms of sleep disturbance.

Genetic counseling: KMT2E-NDD is an autosomal dominant disorder. Most probands reported to date with KMT2E-NDD whose parents have undergone molecular genetic testing have the disorder as the result of a de novo pathogenic variant. Rarely, individuals diagnosed with KMT2E-NDD inherited a pathogenic variant from an affected parent who typically has mild intellectual disability. Each child of an individual with KMT2E-NDD has a 50% chance of inheriting the pathogenic variant. Once the KMT2E pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

PubMed Disclaimer

Similar articles

  • Phelan-McDermid Syndrome-SHANK3 Related.
    Phelan K, Rogers RC, Boccuto L. Phelan K, et al. 2005 May 11 [updated 2024 Jun 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2005 May 11 [updated 2024 Jun 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301377 Free Books & Documents. Review.
  • Myhre Syndrome.
    Lin AE, Brunetti-Pierri N, Lindsay ME, Schimmenti LA, Starr LJ. Lin AE, et al. 2017 Apr 13 [updated 2024 Dec 12]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2017 Apr 13 [updated 2024 Dec 12]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 28406602 Free Books & Documents. Review.
  • SATB2-Associated Syndrome.
    Zarate YA, Bosanko K, Fish J. Zarate YA, et al. 2017 Oct 12 [updated 2024 Jun 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2017 Oct 12 [updated 2024 Jun 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 29023086 Free Books & Documents. Review.
  • TET3-Related Beck-Fahrner Syndrome.
    Fahrner JA. Fahrner JA. 2023 May 18. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2023 May 18. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 37200470 Free Books & Documents. Review.
  • CHD8-Related Neurodevelopmental Disorder with Overgrowth.
    Mitchel MW, Myers SM, Heidlebaugh AR, Taylor CM, Rea H, Neuhaus E, Kurtz-Nelson EC, Earl R, Bernier R, Ledbetter DH, Martin CL, Eichler EE. Mitchel MW, et al. 2022 Oct 27. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2022 Oct 27. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 36302072 Free Books & Documents. Review.
See all similar articles

References

    1. Abreu NJ, Siemon AE, Baylis AL, Kirschner RE, Pfau RB, Ho ML, Hickey SE, Truxal KV. Novel truncating variant in KMT2E associated with cerebellar hypoplasia and velopharyngeal dysfunction. Clin Case Rep. 2022;10:e05277. - PMC - PubMed
    1. Cao Z, Wang C, Chen J, Guo H, Wu C, Zhang G, Ding L. Case report: a novel KMT2E splice site variant as a cause of O'Donnell-Luria-Rodan syndrome in a male patient. Front Pediatr. 2022;10:822096. - PMC - PubMed
    1. Conforti R, Iovine S, Santangelo G, Capasso R, Cirillo M, Fratta M, Caranci F. ODLURO syndrome: personal experience and review of the literature. Radiol Med. 2021;126:316-22. - PubMed
    1. Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjöstedt E, Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten F, Uhlén M. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13:397-406. - PMC - PubMed
    1. Kosma K, Varvagiannis K, Mitrakos A, Tsipi M, Traeger-Synodinos J, Tztis M. 239-kb microdeletion spanning KMT2E in a child with developmental delay: further delineation of the phenotype. Mol Syndromol. 2021;12:321-6. - PMC - PubMed

LinkOut - more resources